PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

IGF-1 LR3 — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

LONG R3IGF-I is an analogue of IGF-I engineered for biopharmaceutical protein production in mammalian cells, supporting growth and survival in serum-free media at concentrations at least 200-fold lower than insulin. · pmid:17172665

Mechanism

It has markedly reduced binding to IGF-binding proteins; in rats it circulated mostly as free peptide and was cleared from plasma faster than IGF-I. · pmid:7693845

Identity

No public registry record is shown for this page: PubChem gave no record that proves it is this substance.

Where the evidence actually sits

Preclinical only100%

Proportion of the 2 claims about IGF-1 LR3 standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I) and an analogue LR3IGF-I in pregnant rats. (1993) · preclinicalLONG R3IGF-I as a more potent alternative to insulin in serum-free culture of HEK293 cells. (2006) · preclinical19932006

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for IGF-1 LR3 yet.

Dose evidence, rung by rung

No established safe human dose. Nothing on file establishes one. That is a statement about the evidence PepJunkie holds, not a promise about the molecule.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier

    nothing resolved on this rung

  3. Observational evidence · resolved human data at the emerging tier: thin, or contested

    nothing resolved on this rung

  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work
    • LONG R3IGF-I as a more potent alternative to insulin in serum-free culture of HEK293 cells. · pmid 17172665 · 2006
    • Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I) and an analogue LR3IGF-I in pregnant rats. · pmid 7693845 · 1993

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.